Method of treating influenza with geranyl-geranyl acetone

Details Method of treating influenza with geranyl-geranyl acetone Method of treating influenza with geranyl-geranyl acetone

2008-03-11

2008-03-11

Chen, Stacy B. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C424S206100

Reexamination Certificate

active

07341988

ABSTRACT:
To provide a novel preventive and/or therapeutic agent against a virus, disclosed is a preventive and/or therapeutic agent against a viral infection containing geranyl-geranyl acetone as an active ingredient. Also, disclosed are inducers for increasing the activity of an anitiviral factor and for protein kinase containing geranyl-geranyl acetone as an active ingredient. Moreover, a method for preventing and/or treating a viral infection which contains administering a patient a effective amount of an agent containing geranyl-geranyl acetone as an active ingredient.

REFERENCES:
patent: 2004/0249219 (2004-12-01), Saucy
patent: 2001-213770 (2001-08-01), None
patent: WO 02/098398 (2002-12-01), None
Yamagami et al. Effects of geranyl-geranyl-acetone administration before heat shock preconditioning for conferring tolerance against ischemia-reperfusion injury in rat livers, J. Lab. Clin. Med. (2000) 135:465-475.
Pavlovic et al., J. Virology, 1992, 66(4):2564-2569.
Unoshima et al. Antimicrobial Agents and Chemotherapy, 2003, 47(9) :2914-2921.
Inoue et al. Antimicrobial Agents and Chemotherapy, May 2005, 49(5):1770-1774.
Encyclopedia of Alternative Medicine, “Boneset”, Belinda Rowland, Apr. 6, 2001, internet print out is three pages.
JPO/NCIPI unverified English language translation of document AL1, JP 2001-213770.
Conti, C., et al., “Antiviral Effects of Hyperthermic Treatment in Rhinovirus Infection,”Antimicrobial Agents Chemother. 43:822-829, American Society for Microbiology (1999).
Couch, R.B., et al., “Influenza: Its Control in Persons and Populations,”J. Infect. Dis. 153:431-440, The University of Chicago Press (1986).
Glezen, W.P., “Serious Morbidity and Mortality Associated with Influenza Epidemics,”Epidemiol. Rev. 4:25-44, The Johns Hopkins University Press (1982).
Gubareva, L.V., et al., “Influenza virus neuraminidase.inhibitors,”Lancet 355:827-835, Lancet Publishing Group (Mar. 2000).
Hayden, F.G., et al., “Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections,”N. Engl. J. Med. 337:874-880, Massachusetts Medical Society (1997).
Hirakawa, T., et al., “Geranylgeranylacetone Induces Heat Shock Proteins in Cultured Guinea Pig Gastric Mucosal Cells and Rat gastric Mucosa,”Gastroenterology 111:345-357, W.B Saunders Company (1996).
Long, J.K., et al., “Antiviral agents for treating influenza,”Cleve. Clin. J. Med. 67:92-95, Cleveland Clinic Educational Foundation (Feb. 2000).
Wingfield, W.L., et al., “Therapeutic Efficacy of Amantadine HCI and Rimantadine HCI in Naturally Occurring Influenza A2 Respiratory Illness in Man,”N. Engl. J. Med. 281:579-584, Massachusetts Medical Society (1969).
Woods, J.M., et al., “4-Guanidino-2,4-Dideoxy-2,3-Dehydro-N-Acetylneuraminic Acid is a Highly Effective Inhibitor Both of the Sialidase (Neuraminidase) and of Growth of a Wide Range of Influenza A and B Viruses In Vitro,”Antimicrobial Agents Chemother. 37:1473-1479, American Society for Microbiology (1993).
The Advisory Committee of Immunization Practices, “Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP),”Morb. Mortal. Wkly. Rep. 46 No. RR-9:1-25 and i-iv, United States Centers for Disease Control (1997).
Ichikawa, T., et al., “Geranylgeranylacetone Induces Antiviral Gene Expression in Human Hepatoma Cells,”BioChem. Biophys. Res. Commun.280:933-939, Academic Press (Jan. 2001).
Tytell, M. and Hooper, P.L., “Heat shock protein: new keys to the development of cytoprotective therapies,”Emerg. Ther. Targets5:267-287, Ashley Publications Ltd. (Apr. 2001).
Supplementary European Search Report for EP Application No. 02770261.2, mailed Nov. 28, 2007, European Patent Office, The Netherlands (2007).

Affiliated with

Also associated with

Rating

Method of treating influenza with geranyl-geranyl acetone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating influenza with geranyl-geranyl acetone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating influenza with geranyl-geranyl acetone will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2812118